Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects

References

• King H, Aubert RE, Hermann WH. Global Burden of Diabetes – 1995–2025: Prevalence, numerical estimates, and projections. Diabetes Care21, 1414–1431 (1998).
   PubMed Web of Science ®Google Scholar
• Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA294, 1255–1259 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr. Rev.19, 477–490 (1998).
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet94, 91–95 (1994).
   Google Scholar
• Pfützner A, Kann P, Pfützner AH et al. Intact and total proinsulin: new aspects for diagnosis and treatment of Type 2 diabetes. Clin. Lab.50, 567–573 (2004).
   PubMedGoogle Scholar
• Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc. Res.55, 250–260 (2002).
   PubMed Web of Science ®Google Scholar
• Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep.3, 279–288 (2003).
   PubMedGoogle Scholar
• Zeng G, Nystrom FH, Ravichandran LV et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation101, 1539–1545 (2000).
   PubMed Web of Science ®Google Scholar
• Ross R. Artherosclerosis: an inflammatory disease. N. Engl. J. Med.340, 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann. Int. Med.130, 933–937 (1999).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med.342, 836–843 (2000).
   PubMed Web of Science ®Google Scholar
• Willerson JT, Ridker PM. Inflammation as cardiovascular risk factor. Circulation109(Suppl.1), II2–II10 (2004).
   PubMedGoogle Scholar
• Cipollone F, Mezzetti A, Porreca E et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation106, 399–402 (2002).
   PubMed Web of Science ®Google Scholar
• Varo N, Vicent D, Libby P et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation107, 2664–2669 (2003).
   PubMed Web of Science ®Google Scholar
• Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation103, 2531–2534 (2001).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care28(Suppl 1), S4-S36 (2005). Erratum in: Diabetes Care28, 990 (2005).
   PubMed Web of Science ®Google Scholar
• UKPDS Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet.352, 837–853 (1998). Erratum in: Lancet354, 602 (1999).
   PubMed Web of Science ®Google Scholar
• Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol. Ther.6, 850–863 (2004).
   PubMedGoogle Scholar
• Granberry MC, Fonseca VA. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am. J. Cardiovasc. Drugs5, 201–209 (2005).
   PubMedGoogle Scholar
• Pfützner A, Schöndorf T, Seidel D et al. Impact of rosiglitazone on β-cell function, insulin resistance and adiponectin concentrations – results from a double blind oral combination study with glimepiride. Metabolism55, 20–25 (2006).
   Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care28, 1547–1554 (2005).
   PubMed Web of Science ®Google Scholar
• Van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in Type 2 diabetes. Arterioscler. Thromb. Vasc. Biol.23, 1744–1749 (2003).
   PubMed Web of Science ®Google Scholar
• Wellington K. Rosiglitazone/Metformin. Drugs65, 1581–1592 (2005).
   PubMed Web of Science ®Google Scholar
• Barlocco D. Muraglitazaar (Bristol-Myers Squibb/Merck). Curr. Opin. Investig. Drugs6, 427–434 (2005).
   PubMedGoogle Scholar
• Kamber N, Davis TM. Tesaglitazaar (AstraZeneca). I. Drugs8, 927–935 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K, Topol EJ. Effect of muraglitazaar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA294, 2581–2586 (2005).
   PubMed Web of Science ®Google Scholar
• Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature405, 421–424 (2000).
   PubMed Web of Science ®Google Scholar
• Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet355, 1008–1010 (2000).
   PubMed Web of Science ®Google Scholar
• Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor γ. J. Mol. Med.79, 30–47 (2001).
   PubMed Web of Science ®Google Scholar
• Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev.20, 649–688 (1999).
   PubMed Web of Science ®Google Scholar
• Auwerx J. PPARγ, the ultimate thrifty gene. Diabetologia42, 1033–1042 (1999).
   PubMed Web of Science ®Google Scholar
• Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol.19, 546–551 (1999).
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Roden M, Urquhart R et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with Type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia.48, 553–560 (2005).
   PubMed Web of Science ®Google Scholar
• Tan MH, Glazer NB, Johns D, Widel M, Gilmore KJ. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with Type 2 diabetes. Curr. Med. Res. Opin.20, 723–728 (2004).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Johns D, Widel M, Eckland DJ, Gilmore KJ, Tan MH. Comparison of the effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with Type 2 diabetes. Diabetes Care28, 266–272 (2005).
   PubMedGoogle Scholar
• Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with Type 2 diabetes. Diabetes Care27, 141–147 (2004).
   PubMed Web of Science ®Google Scholar
• Winkler K, Konrad T, Füllert S et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care26, 2588–2594 (2003).
   PubMed Web of Science ®Google Scholar
• Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation101, 235–238 (2000).
   PubMed Web of Science ®Google Scholar
• Pfützner A, Marx N, Lübben G et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control - results from the Pioneer Study. J. Am. Coll. Card.45, 1925–1931 (2005).
   PubMed Web of Science ®Google Scholar
• Gillies PS, Dunn CJ. Pioglitazone. Drugs60, 333–343 (2000).
   PubMed Web of Science ®Google Scholar
• Maeshiba Y Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new anti-diabetic agent pioglitazone in rats, dogs and monkeys. Arzneim.Forsch/Drug Res.47, 1–29 (1997).
   Google Scholar
• Hagiwara T. Pharmacokinetic study of AD-4833 in the elderly. Jap. J. Clin. Exp. Med.74, 1307 (1997).
   Google Scholar
• Hiraga K. Results of clinical Phase I study on AD-4833 – single dose and repeated dose studies in healthy adult subjects. Jap. J. Clin. Exp. Med.74, 1184 (1997).
   Google Scholar
• Eckland DA et al. Clinical pharmacokinetics of pioglitazone. Exp. Clin. Endocrinol. Diabetes49(Suppl. 2A), S234–S242 (2000).
   Google Scholar
• Prueksaritanont T, Vega JM, Zhao J et al. Interactions between simvastatin and troglitazone or pioglitazone in healthy subects. J. Clin. Pharmacol.41, 573–581 (2000).
   Google Scholar
• Yamazaki H, Suzuki M, Tane K, Shimada N, Nakajima M, Yokoi T. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P 450 isoenzymes: comparison with pioglitazone or rosiglitzone. Xenobiotica20, 61–70 (2000).
   Google Scholar
• Diamant M, Heine RJ. Thiazolidinediones in Type 2 diabetes mellitus: current clinical evidence. Drugs63, 1373–1405 (2003).
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Thiazolidinediones. N. Engl. J. Med.351, 1106–1118 (2004).
   PubMed Web of Science ®Google Scholar
• Scherbaum WA, Goke B; German Pioglitazone Study Group. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with Type 2 diabetes: a double-blind, placebo-controlled study. Horm. Metab. Res.34(10), 589–595 (2002).
   PubMed Web of Science ®Google Scholar
• Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL; The Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care23, 1605–1611 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with Type 2 diabetes mellitus. Coron. Artery Dis.12, 413–423 (2001).
   PubMed Web of Science ®Google Scholar
• Herz M, Johns D, Reviriego J et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with Type 2 diabetes mellitus. Clin. Ther.25, 1074–1095 (2003).
   PubMed Web of Science ®Google Scholar
• Pavo I, Jermendy G, Varkonyi TT et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab.88, 1637–1645 (2003).
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group. Efficacy and safety of pioglitazone versus metformin in patients with Type 2 diabetes mellitus: a double-blind, randomized trial. J. Clin. Endocrinol. Metab.89, 6068–6076 (2004). Erratum in: J. Clin. Endocrinol. Metab.90, 746 (2005).
   PubMed Web of Science ®Google Scholar
• Tan MH, Johns D, Strand J et al. Sustained effects of pioglitazone vs glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet. Med.21, 859–866 (2004).
   PubMed Web of Science ®Google Scholar
• Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P; QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet. Med.22, 399–405 (2005).
   PubMed Web of Science ®Google Scholar
• Pfützner A, Hohberg C, Lübben G et al. Pioneer Study: PPARγ-Activation results in an overall improvement of clinical and metabolic markers associated with insulin resistance independent from long-term glucose control. Horm. Metab. Res.37, 510–515 (2005).
   PubMed Web of Science ®Google Scholar
• Göke B; German Pioglitazone Study Group. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with Type 2 diabetes mellitus. Treat. Endocrinol.1, 329–336 (2002).
   PubMedGoogle Scholar
• Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr. Pract.7, 162–169 (2001). Erratum in: Endocr. Pract.7, 330 (2001).
   PubMedGoogle Scholar
• Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with Type 2 diabetes who were previously treated with troglitazone. Diabetes Care25, 708–711 (2002).
   PubMed Web of Science ®Google Scholar
• Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with Type 2 diabetes mellitus: a randomized, placebo-controlled study. Am. J. Med.111, 10–17 (2001).
   Google Scholar
• Derosa G, Cicero AF, Gaddi A et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in Type 2 diabetic patients with the metabolic syndrome. Diabetes Res. Clin. Pract.69, 5–13 (2005).
   PubMed Web of Science ®Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL; The Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of Type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin. Ther.22, 1395–1409 (2000).
   PubMed Web of Science ®Google Scholar
• Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with Type 2 diabetes: a randomized, comparative study. Diabetes Metab. Res. Rev.21, 167–174 (2005).
   PubMed Web of Science ®Google Scholar
• Jovanovic L, Hassman DR, Gooch B et al. Treatment of Type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.Diabetes Res. Clin. Pract.63, 127–134 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S; Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in Type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int. J. Clin. Pract.56, 251–257 (2002).
   PubMed Web of Science ®Google Scholar
• Mattoo V, Eckland D, Widel M et al. Metabolic effects of pioglitazone in combination with insulin in patients with Type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin. Ther.27, 554–567 (2005).
   PubMed Web of Science ®Google Scholar
• King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones (Letter). Diabetes Care23, 557 (2000).
   PubMed Web of Science ®Google Scholar
• Szapary PO, Bloedon LT, Samaha FF et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler. Thromb. Vasc. Biol.26, 182–188 (2006).
   PubMed Web of Science ®Google Scholar
• Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs62, 1463–1480 (2002).
   PubMed Web of Science ®Google Scholar
• Forst T, Lübben G, Hohberg C et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus Type 2. Microcirculation12, 543–550 (2005).
   PubMed Web of Science ®Google Scholar
• Negro R, Dazzi D, Hassan H, Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol.29, 11–17 (2004).
   PubMedGoogle Scholar
• Füllert S, Schneider F, Haak E et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab.87, 5503–5506 (2002).
   PubMed Web of Science ®Google Scholar
• Schöndorf T, Forst T, Hohberg C et al. The IRIS III - Study: Pioglitazone improves metabolic control and blood pressure in patients with Type 2 diabetes without increasing body weight. Diab. Obes. Metab. (accepted, in press).
   Google Scholar
• Hirayama H, Sugano M, Abe N, Yonemoch H, Makino N. Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients. Int. J. Cardiol.77, 75–79 (2001).
   PubMed Web of Science ®Google Scholar
• Horio T, Suzuki M, Suzuki K et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am. J. Hypertens.18, 949–957 (2005).
   PubMed Web of Science ®Google Scholar
• Nakamura T, Matsuda T, Kawagoe Y et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in Type 2 diabetic nephropathy patients. Metabolism.53, 1382–1386 (2004).
   PubMed Web of Science ®Google Scholar
• Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in Type 2 diabetes. J. Clin. Endocrinol. Metab.86, 3452–3456 (2001).
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler. Thromb. Vasc. Biol.24, 930–934 (2004).
   PubMed Web of Science ®Google Scholar
• Hetzel J, Balletshofer B, Rittig K et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler. Thromb. Vasc. Biol.25, 1804–1809 (2005).
   PubMed Web of Science ®Google Scholar
• Langenfeld M, Forst T, Hohberg C et al. Pioglitazone decreases carotid intima-media thickness independent of glycemic control in patients with Type 2 diabetes mellitus. Circulation111, 2525–2531 (2005).
   PubMed Web of Science ®Google Scholar
• Forst T, Hohberg C, Fuellert S et al. Pharmacological PPARγ stimulation in contrast to β cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with Type 2 diabetes. Horm. Metab. Res.37, 521–527 (2005).
   PubMedGoogle Scholar
• Satoh N, Ogawa Y, Usui T et al. Antiatherogenic effect of pioglitazone in Type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care22, 2493–2499 (2003).
   Google Scholar
• Horio T, Suzuki M, Takamisawa I et al. Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am. J. Hypertens.18, 1626–1630 (2005).
   PubMed Web of Science ®Google Scholar
• Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol.23, 52–57 (2003).
   PubMed Web of Science ®Google Scholar
• Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with Type 2 diabetes. J. Cardiovasc. Pharmacol.46, 773–778 (2005).
   PubMed Web of Science ®Google Scholar
• Bodary PF, Vargas FB, King SA, Jongeward KL, Wickenheiser KJ, Eitzman DT. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J. Thromb. Haemost.3, 2149–2153 (2005).
   PubMed Web of Science ®Google Scholar
• Li D, Chen K, Sinha N et al., The effects of PPAR-γ ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc. Res.65, 907–912 (2005).
   PubMed Web of Science ®Google Scholar
• Wakino S, Hayashi K, Kanda T, et al., Peroxisome proliferator-activated receptor γ ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res.95, e45–e55 (2004).
   Google Scholar
• Sumita C, Maeda M, Fujio Y et al. Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage. Biochim. Biophys. Acta.1673, 115–121 (2004).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J; The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia47, 1519–1527 (2004).
   PubMed Web of Science ®Google Scholar
• Le Feuvre C. Cardiovascular effects of rosiglitazone. Presse Med.33, 735–745 (2004).
   Google Scholar
• Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A; PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care27, 1647–1653 (2004).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland EJA et al. on behalf of the Proactive investigators. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet366, 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: a review of its use in Type 2 diabetes mellitus. Drugs66, 85–109 (2006)
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Belcher G. Safety profile of pioglitazone. Int. J. Clin. Pract.121(Suppl.), 27–31 (2001).
   Google Scholar
• Niemeyer NV, Janney LM. Thiazolidine - induced edema. Pharmacotherapy22, 924–929 (2002).
   PubMed Web of Science ®Google Scholar
• Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet. Med.22, 973–979 (2005).
   PubMed Web of Science ®Google Scholar
• Farley-Hills E, Sivasankar R, Martin M. Fatal liver failure associated with piogliotazone. Br. Med. J.329, 429 (2004).
   PubMed Web of Science ®Google Scholar
• Nagasaka S, Abe T, Kawakami T et al. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabet. Med.19, 347–348 (2002).
   PubMedGoogle Scholar
• May LD, Levkowitch JH, Kram MT et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann. Intern. Med.136, 449–452 (2002).
   PubMed Web of Science ®Google Scholar
• Rubin CJ et al. Pioglitazone liver enzyme profile is similiar to placebo in US controlled clinical trials. Diabetes49, 500 (2000).
   PubMedGoogle Scholar
• Marcy TR, Britton ML, Blevins SM. Second generation thiazolidinediones and hepatotoxicity. Ann. Pharmacother.38, 1419–1423 (2004).
   PubMed Web of Science ®Google Scholar
• Tan MH, Baksi A, Krahulec B et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with Type 2 diabetes. Diabetes Care28, 544–549 (2005).
   PubMed Web of Science ®Google Scholar
• Belcher G et al. Weight changes with treatment of Type 2 diabetes with pioglitazone, metformin and gliclazide. Diabetes52(Suppl1), 474-P (2003).
   Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. J. Clin. Endocrinol. Metab.87, 2784–2791 (2002).
   PubMed Web of Science ®Google Scholar
• Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation111, 583–590 (2005).
   PubMed Web of Science ®Google Scholar
• Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet. Med.22, 986–993 (2005).
   PubMed Web of Science ®Google Scholar
• Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT. Association between congestive heart failure and hospitalization in patients with Type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin. Ther.26, 1400–1410 (2004).
   PubMed Web of Science ®Google Scholar
• Patel C, Wyne KL, McGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab. Vasc. Dis. Res.2, 61–66 (2005).
   PubMedGoogle Scholar
• Howard B, Rodriguez B, Bennet P et al. Prevention Conference VI: diabetes and cardiovascular disease: Writing group I: epidemiology. Circulation105, e132–e137 (2002).
   Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med.339, 229–234 (1998).
   PubMed Web of Science ®Google Scholar
• Smith SA. Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones. Biochimie85, 1219–1230 (2003).
   PubMed Web of Science ®Google Scholar
• Feher T, Bodrogi L, Vallent K, Ribai Z. Role of human adipose tissue in the production and metabolism of steroid hormones. Endokrinologie80, 173–180 (1982).
   PubMedGoogle Scholar
• Yki-Jarvinen H. Insulin resistance and endothelial dysfunction. Best. Pract. Res. Clin. Endocrinol. Metab.17, 411–430 (2003).
   Google Scholar
• Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in Type 2 diabetes. Arterioscler. Thromb. Vasc. Biol.26, 28–40 (2006).
   Google Scholar
• Szapary PO, Bloedon LT, Samaha FF et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler. Thromb. Vasc. Biol.26, 182–188 (2006).
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Marx N. Pfützner A et al. Anti-Inflammatory power of pioglitazone, simvastatin and their combination in non-diabetic high cardiovascular rsik patients with elevated hsCRP. Diabetes114(Suppl.1), 433-P (2006).
   Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch. Intern. Med.344, 1383–1389 (1994).
   Google Scholar
• Keech A, Colquhoun D, Best J et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care26, 2713–2721 (2003).
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant survivors of myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation98, 2513–2519 (1998).
   PubMed Web of Science ®Google Scholar
• Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet355, 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet366, 1241–1242 (2005).
   PubMed Web of Science ®Google Scholar